Business Wire

PerkinElmer Receives AOAC INTERNATIONAL First Action Official Methods of Analysis (OMA) Status for Solus One Salmonella Assay

11.5.2020 16:00:00 EEST | Business Wire | Press release

Share

PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced its Solus One™ Salmonella assay and methods have been granted First Action Official Methods of Analysis℠ (OMA) status, number 2020.03, from AOAC INTERNATIONAL (Association of Official Analytical Collaboration).

The Solus One Salmonella assay, which previously received ISO 16140 and AOAC Performance Tested Methods℠ (PTM) certification, detects Salmonella in select foods, with negative/presumptive positive results available in approximately 2 hours, post enrichment. Positive confirmation is then possible with an additional 24 hours. The assay can be run manually or with automation by adding Dynex Technologies’ DS-2® system.

Achieving OMA, the highest level of AOAC certification, involved a rigorous certification process that included simultaneous testing at over a dozen labs across the US, UK and South Africa. Data was then closely reviewed by an expert panel confirming result accuracy and repeatability of the Solus One Salmonella assay for a range of samples including raw salmon, romaine lettuce, cheddar cheese, instant non-fat dry milk, pasteurized liquid eggs, raw beef trim, cocoa, and herbs and spices. Tested food sample sizes ranged from 25g to 375g and swabs and sponges for production environment testing were also included.

“The World Health Organization estimates that Salmonella causes over 17 million people to become ill each year globally,” said Greg Sears, vice president and general manager, Food, PerkinElmer. “Members of the food industry, regulatory and research ecosystem around the world need to be able to depend on pathogen testing options that are reliable, consistent and efficient. We are pleased that our Solus One Salmonella assay and methods -- which have already been helping with food safety and quality globally -- have now achieved the highest level of AOAC certification.”

PerkinElmer’s pathogen assay offerings also include Solus One for Listeria and E. coli O157 and are part of the company’s broad food safety and quality solutions portfolio spanning across instruments, software, testing kits, reagents and services for grain, dairy, meats, produce, edible oils, seafood, herbs and spices and more. For more information please visit www.perkinelmer.com/category/food-safety-quality.

About PerkinElmer
PerkinElmer enables scientists, researchers and clinicians to address their most critical challenges across science and healthcare. With a mission focused on innovating for a healthier world, we deliver unique solutions to serve the diagnostics, life sciences, food and applied markets. We strategically partner with customers to enable earlier and more accurate insights supported by deep market knowledge and technical expertise. Our dedicated team of about 13,000 employees worldwide is passionate about helping customers work to create healthier families, improve the quality of life, and sustain the wellbeing and longevity of people globally. The Company reported revenue of approximately $2.9 billion in 2019, serves customers in 190 countries, and is a component of the S&P 500 index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Jennifer McNeil
+1 508 361-5901
Jennifer.mcneil@perkinelmer.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

DEFINITIVE Trial Reaches Major Milestone: All Centres Approved and More Than 50% Recruitment Achieved7.5.2026 12:21:00 EEST | Press release

The DEFINITIVE project, a landmark European Union-funded international phase III clinical trial evaluating the use of the HER2DX diagnostic assay to guide personalised treatment in early-stage HER2-positive breast cancer (BC), announces two major operational milestones at the ESMO Breast Cancer 2026 congress. Approvals have been obtained in the 7 participating countries, 33 clinicals sites are now open for patient recruitment. The trial has reached over 50% of its recruitment target, marking a pivotal moment on the path toward to transforming HER2-positive BC treatment. About the DEFINITIVE Project The DEFINITIVE project is a 5-year, prospective, open-label, randomised, two-arm phase III international clinical trial conducted across 44 centres in 7 European member states and associated countries. The trial aims to demonstrate that personalising treatment decisions for patients with early-stage (stage II to IIIA) HER2-positive BC using the HER2DX genomic diagnostic assay can improve pat

The AI Summit London Unveils 10th Anniversary Speaker Line-Up Featuring Global Leaders in Enterprise AI7.5.2026 11:00:00 EEST | Press release

The AI Summit London today unveiled its keynote speaker line-up for the event’s 10th anniversary edition, bringing together senior leaders, technologists and policymakers from across the globe. The 2026 programme will explore the transformative power of artificial intelligence across sectors including government, enterprise, healthcare, finance and AI infrastructure. Speakers from NVIDIA, Amazon Web Services, Virgin Atlantic, AstraZeneca, the Tony Blair Institute for Global Change and JPMorgan Chase will explore AI deployment, governance, infrastructure and customer transformation across major industries. Further, Jim Carter, Director General Commercial and Industry at the Ministry of Defence, Ollie Ilott, Interim Director General, Emerging Technology and AI, UK Government, and Sasha Rubel, Head of AI/Generative AI Policy, EMEA, Amazon Web Services will lead the “AI Sovereignty – Possibility or Pipe Dream for Europe?” panel, debating whether Europe can realistically compete in the glob

MOVIVA ® launch spotlight at ESGE Days 20267.5.2026 10:58:00 EEST | Press release

During its 175th anniversary year, Erbe Elektromedizin GmbH highlights its continued commitment to healthcare innovation with the launch of MOVIVA®, a minimally invasive solution for gastric mucosal ablation (GMA) in endoscopic obesity therapy. MOVIVA® will be the central focus of Erbe’s activities at ESGE Days in Milan, 14–16 May 2026. Physicians can explore the technology in the hands-on area and attend a dedicated symposium. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507842222/en/ How GMA with MOVIVA® works “Obesity continues to rise worldwide, and many patients still face a gap between lifestyle interventions, pharmacotherapy, and bariatric surgery. Endoscopic approaches are emerging as additional treatment options. With MOVIVA®, we aim to support physicians in bringing this innovative treatment option into clinical practice and expanding access to minimally invasive obesity therapies.” Marcus Felstead, Chief Comm

Resilience Takes Center Stage as Europe’s LEED Community Gathers in Milan for GBCI Europe Circle 20267.5.2026 10:57:00 EEST | Press release

Green Business Certification Inc. Europe (GBCI), is hosting Circle 2026, the annual flagship event of the European LEED community, taking place in Milan from May 6–8 and marking its fifth anniversary. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260506692329/en/ Porta Nuova, Milan - LEED v4.1 Communities: Existing, Gold certification. Photo courtesy of COIMA. At the center of discussions is LEED v5, the latest version of the world’s most widely used green building rating system, as a bridge to EU Taxonomy alignment - a critical priority for the European market, where regulatory pressure and investor demand are accelerating the integration of certification, finance, and ESG reporting. GBCI Europe Impact Report 2026: European Real Estate Shifts from Sustainability to Risk Management As part of the main conference program, Peter Templeton, President and CEO of USGBC and GBCI will present the GBCI Europe Impact Report 2026, ba

Criteo Selects Navan to Modernize Global Travel Management7.5.2026 10:00:00 EEST | Press release

Navan (NASDAQ: NAVN), the global AI-powered business travel and expense platform, today announced that it has been selected by Criteo, the global commerce intelligence platform, to modernize its global travel program. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507251188/en/ Global commerce intelligence platform delivers high employee satisfaction with Navan Criteo set out to provide its global workforce with an easy-to-use travel booking experience that brought visibility and control to its travel spending. Prioritizing operational excellence and employee experience, Criteo selected Navan because of its extensive inventory, unified travel and payments platform, and global expertise in sustainability reporting. “We wanted to give our teams a travel tool that’s as easy to use as the apps they use in their personal lives,” said Sarah Glickman, Chief Financial Officer at Criteo. “Our goal with Navan was to improve the use

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye